Lipella pharmaceuticals launches innovative registry to advance oral lichen planus research

Affecting about 6 million americans, olp is a chronic inflammatory disease affecting the mucous membranes of the mouth no fda-approved therapy currently exists for olp patient registry and olp study information is now available pittsburgh, aug. 22, 2024 (globe newswire) -- lipella pharmaceuticals, inc. (nasdaq: lipo) has launched an oral lichen planus (olp) patient registry. this online platform is designed to enhance research and drive the development of new treatments for olp, a chronic inflammatory disease affecting the mucous membranes of the mouth.
LIPO Ratings Summary
LIPO Quant Ranking